Clazakizumab

Summary

Clazakizumab (CHEMBL2108589) is a phase-3 clinical-stage antibody; indicated across 10 conditions including rheumatoid arthritis and crohn disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 10 conditions
• Clinical trials: 18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108589
Name	Clazakizumab
Type	Antibody
Max phase	3

Also known as: ALD-518, ALD518, BMS-945429, Clazakizumab, CLAZAKIZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
rheumatoid arthritis	2	MONDO:0008383	EFO:0000685
Crohn disease	2	MONDO:0005011	EFO:0000384
psoriatic arthritis	2	MONDO:0011849	EFO:0003778
stomatitis	2	MONDO:0004842	EFO:1001904
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
asthma	2	MONDO:0004979	MONDO:0004979
graft versus host disease	1	MONDO:0013730	EFO:0004599

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE2	14
PHASE1/PHASE2	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03744910	PHASE3	TERMINATED	Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
NCT03380962	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
NCT05727384	PHASE2	ACTIVE_NOT_RECRUITING	Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study
NCT00866970	PHASE2	COMPLETED	Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
NCT00867516	PHASE2	COMPLETED	Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis
NCT01373151	PHASE2	COMPLETED	Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
NCT01403064	PHASE2	TERMINATED	Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
NCT01490450	PHASE2	COMPLETED	Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
NCT01530256	PHASE1/PHASE2	TERMINATED	Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
NCT01545050	PHASE2	TERMINATED	Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn’s Disease
NCT02015520	PHASE2	COMPLETED	Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
NCT03380377	PHASE1/PHASE2	COMPLETED	Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant
NCT03444103	PHASE2	COMPLETED	A Pilot Trial of Clazakizumab in Late ABMR
NCT04129931	PHASE2	COMPLETED	PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study
NCT04343989	PHASE2	COMPLETED	A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
NCT04348500	PHASE2	COMPLETED	Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)
NCT04381052	PHASE2	TERMINATED	Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
NCT04494724	PHASE2	UNKNOWN	Clazakizumab vs. Placebo - COVID-19 Infection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).